[New aspects of carcinoma of the breast therapy and of gynaecological carcinoma treatment].
Dose-dense chemotherapy and high dose chemotherapy have been issued in the adjuvant and primary therapy of breast cancer. Should we use GnRH analogues after chemotherapy in premenopausal women who have not become amenorrheic through chemotherapy? How important are the taxanes in the primary and adjuvant treatment of breast cancer? The optimal screening method for women at high-risk for breast cancer was addressed as one of the most important topics. Primary and recurrent ovarian cancer therapy needs to be improved further. The optimal primary therapy for endometrial cancer and cervical cancer with radiotherapy and/or chemotherapy was another addressed issue.
Loibl
S
S
Universitätsfrauenklinik Frankfurt am Main, Germany. loibl@em.uni-frankfurt.de
Von Minckwitz
G
G
Kaufmann
M
M
D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D005833:Genital Neoplasms, Female / Q000628:therapy*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans
D007987:Gonadotropin-Releasing Hormone